Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA to manufacture and market Eltrombopag Tablets in four strengths — 12.5 mg, 25 mg, 50 mg, and 75 mg. Eltrombopag is a generic version of the drug Promacta, widely used to treat low platelet counts in conditions like immune thrombocytopenia (ITP) and chronic hepatitis C. This clearance allows the company to launch the product in the US market, one of the world's largest pharmaceutical markets. The approval strengthens Zydus's growing US generics portfolio.
Positive for shareholders. USFDA approvals typically boost US business revenue, and Eltrombopag has a sizeable market opportunity, which may support future earnings growth from the company's US formulations segment.